|
Delayed
OTC Markets
13:03:16 2026-09-10 EDT
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -.--% |
|
-.--% | -99.80% |
| Market Cap | 1.3M 1.16M 1.09M 987K 1.86M 126M 1.87M 13.06M 5.1M 64.14M 4.89M 4.79M 206M | P/E 2023 |
-2.13x | P/E 2024 | -2.52x |
|---|---|---|---|---|---|
| Enterprise Value | 7.55M 6.75M 6.29M 5.72M 10.77M 730M 10.85M 75.64M 29.55M 371M 28.35M 27.74M 1.19B | EV / Sales 2023 |
394,366,816x | EV / Sales 2024 | 171,944,593x |
| Free-Float |
100% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 month | 0 | 0 | |
| Current year | 0 | 0.01 | |
| 1 year | 0 | 0.01 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 2.15 | |
| 10 years | 0 | 4.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | - | |
Radka Milanova
CTO | Chief Tech/Sci/R&D Officer | 71 | - |
James Smeeding
PRN | Corporate Officer/Principal | - | 2020-05-01 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
James Smeeding
BRD | Director/Board Member | - | 2020-05-01 |
Abdul Nnyenje
BRD | Director/Board Member | - | 2024-10-20 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/25/23 | Buy | Director | 80,000 | 0.0824% | ||
| 9/22/20 | Buy | Chief Executive Officer | 10,000 | 0.0118% | ||
| 9/22/20 | Other | Chief Executive Officer | 0 | 0% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | - | - | 117 | ||
| -3.26% | +1.19% | +37.58% | +103.49% | 1,060B | ||
| -1.73% | -0.99% | +35.02% | +61.54% | 623B | ||
| -0.85% | +3.99% | +16.90% | +81.28% | 480B | ||
| -1.66% | -1.72% | +63.59% | +35.25% | 352B | ||
| -1.33% | +2.12% | +22.35% | +42.08% | 345B | ||
| -1.72% | +0.41% | +11.31% | +34.51% | 274B | ||
| -1.81% | -2.04% | -5.87% | +10.81% | 249B | ||
| -2.17% | +0.21% | +38.52% | +50.29% | 223B | ||
| -0.77% | -0.26% | +24.41% | +96.00% | 182B | ||
| Average | -1.51% | -0.44% | +27.09% | +57.25% | 378.8B | |
| Weighted average by Cap. | -1.94% | +0.04% | +30.23% | +67.26% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 0.07 0.06 0.06 0.05 0.1 6.97 0.1 0.72 0.28 3.55 0.27 0.26 11.4 | 0.1 0.09 0.08 0.07 0.14 9.3 0.14 0.96 0.38 4.73 0.36 0.35 15.21 |
| Net income | -10.68M -9.54M -8.9M -8.08M -15.22M -1.03B -15.34M -107M -41.78M -525M -40.08M -39.21M -1.69B | -3.98M -3.55M -3.31M -3.01M -5.67M -385M -5.71M -39.83M -15.56M -196M -14.93M -14.6M -629M |
| Net Debt | 5.65M 5.05M 4.71M 4.28M 8.06M 547M 8.12M 56.62M 22.12M 278M 21.22M 20.76M 894M | 6.25M 5.58M 5.21M 4.73M 8.91M 604M 8.98M 62.58M 24.45M 307M 23.45M 22.95M 988M |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- ALID Stock
Select your edition
All financial news and data tailored to specific country editions
















